Cure or control strategies for difficult cancers remained active as clinical-stage and translational programs pushed forward. In glioblastoma, GLORIA trial results combine an L-RNA aptamer approach that inhibits CXCL12 with radiotherapy and bevacizumab, with early-phase outcomes described as promising for newly diagnosed patients. In hematology, early-stage myeloma data also highlighted a Phase 2 D-PRISM effort testing daratumumab across precursor states, including high-risk MGUS and low-risk smoldering multiple myeloma. These studies add to the broader shift toward earlier intervention in biologically defined disease states. Meanwhile, targeted therapy discovery work continued through reports on new molecular mechanisms and drug-target interactions designed to expand options for refractory patient populations.